Drugs / Tinostamustine
Tinostamustine
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05432375 | Jul 2022 → Nov 2024 | glioblastoma | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03903458 | Mar 2019 → Dec 2021 | melanoma | Markus Joerger | Unknown | No outcome recorded |
| Phase 1 | NCT03452930 | Aug 2018 → Jun 2024 | gliosarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02576496 | Apr 2016 → May 2023 | Hodgkins lymphoma, plasma cell myeloma, primary cutaneous T-cell lymphoma | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03687125 | Oct 2018 → Apr 2019 | plasma cell myeloma | Mundipharma-EDO GmbH | Terminated | No outcome recorded |
| Phase 1/2 | NCT03345485 | Nov 2017 → Jul 2022 | endometrial cancer, ovarian cancer, small cell lung carcinoma, soft tissue sarcoma +1 | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tinostamustine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03903458 ↗ |
| Known as | EDO-S101 | “fusion molecule Tinostamustine (EDO-S101) and the anti-PD-1 monoclonal antibody Nivolumab” NCT03903458 ↗ |
| Known as | Tinostamustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989941 ↗ |
| Action | Inhibit | “Tinostamustine, a novel alkylating deacetylase inhibitor, inhibits tumor cell growth” PMID 39617826 ↗ Jan 2025 |
| Modality | Other / unclassified | “alkylating histone deacetylase inhibition (HDACi) fusion molecule” NCT03903458 ↗ |
| Route | Intravenous | “Tinostamustine as a single agent administered by IV infusion” NCT02576496 ↗ |